Probiotec Ltd
ASX:PBP

Watchlist Manager
Probiotec Ltd Logo
Probiotec Ltd
ASX:PBP
Watchlist
Price: 2.98 AUD Market Closed
Market Cap: 242.3m AUD
Have any thoughts about
Probiotec Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

15.4
Current
14.5
Median
13.7
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
15.4
=
Enterprise Value
308.6m AUD
/
EBITDA
20m AUD
All Countries
Close
Market Cap EV/EBITDA
AU
Probiotec Ltd
ASX:PBP
242.3m AUD 15.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 459 134.4
US
Eli Lilly and Co
NYSE:LLY
734.5B USD 47.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 19.9
US
Johnson & Johnson
NYSE:JNJ
352B USD 11.6
US
Merck & Co Inc
NYSE:MRK
255.8B USD 10.6
CH
Roche Holding AG
SIX:ROG
211.7B CHF 10.3
UK
AstraZeneca PLC
LSE:AZN
165.4B GBP 169.6
CH
Novartis AG
SIX:NOVN
177.1B CHF 9.6
US
Pfizer Inc
NYSE:PFE
153.7B USD 10.7
EBITDA Growth EV/EBITDA to Growth
AU
Probiotec Ltd
ASX:PBP
Average EV/EBITDA: 415.1
15.4
35%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.2
42%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
19.9
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.6
4%
2.9
US
Merck & Co Inc
NYSE:MRK
10.6
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.3
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.6
18%
9.4
CH
Novartis AG
SIX:NOVN
9.6
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.7
9%
1.2

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
7.8
2-Years Forward
EV/EBITDA
6.7
3-Years Forward
EV/EBITDA
5.9